More To Go Or Is It Over? – Applied Dna Sciences Inc (APDN)

Applied Dna Sciences Inc (NASDAQ:APDN) does about 928.70K shares in volume on a normal day but saw 849858 shares change hands in the recent trading day. The company now has a market cap of 4.13M USD. Its current market price is $0.46, marking an increase of 7.64% compared to the previous close of $0.43. The 52 week high reached by this stock is $37.20 whilst the lowest price level in 52 weeks is $0.33. The script in recent trading has seen the stock touch a high of $1.5 and a low of $1.5.

Applied Dna Sciences Inc (APDN) has a 20-day trading average at $0.4623 and the current price is -98.77% off the 52-week high compared with 38.79% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.6208 and its 200-day simple moving average is $10.8816. If we look at the stock’s price movements over the week, volatility stands at 24.73%, which decreases to 16.44% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 28.42 to suggest the stock is oversold.

The consensus objective for the share price is $1.50, suggesting that the stock has a potential upside of 69.33% over the period. The median price target is 69.33% away from the current levels at $1.5.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 12, 2021 when ROTH Capital initiated the stock to “Buy” and issued a price target of $24. H.C. Wainwright reiterated its price target at $20-$12.

Applied Dna Sciences Inc (APDN) stock is down -15.96% over the week and -15.98% over the past month. Its price is -96.29% year-to-date and -98.25% over the past year.

Its 12-month price target is $1.5. To reach the target analysts have set, the stock logically needs to grow 69.33 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $1.5, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $1.5.

The company has a return on investment of -2946.59% and return on equity of -246.31%. The beta has a value of 0.09. Price to sales ratio is 0.75.